Skip to content

Study · Systematic review · n = 614 · 2019

6 results

Comparative effectiveness of exenatide once-weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta-analysis of observational studies.

Fadini GP, Bonora BM, Lapolla A, Fattor B, Morpurgo PS, Simioni N, Avogaro A

Diabetes, obesity & metabolism22 Jan 2019Cited by 11 (Europe PMC)

PMID30578607 (opens in a new tab)PMCIDPMC6590315 (opens in a new tab)DOI10.1111/dom.13623 (opens in a new tab)PepBankPUB-30578607
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of observational studies, the change in HbA1c was the same with liraglutide and exenatide once weekly.

    In plain wordsPooling real-world studies, HbA1c fell by the same amount with liraglutide and exenatide once weekly.

    Peptide
    Liraglutide
    Outcome
    No significant changePooled HbA1c change versus ExeOW
    Study

    n: not reported in source

    Comparator
    Exenatide once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pooling these data with those of observational studies available in the literature yielded superimposable effects between the two groups for the change in HbA1c and body weight, with a higher risk of discontinuation (mainly based on pharmacy refill rates) for ExeOW.
    1 context sentence
    Summary · context
    In this study, we retrospectively compared the effectiveness of exenatide once-weekly (ExeOW) versus liraglutide in non-insulin treated patients with type 2 diabetes followed under routine care.
  2. 02HumanSystematic reviewEfficacy outcome

    In a meta-analysis of observational studies, the change in body weight was the same with liraglutide and exenatide once weekly.

    In plain wordsPooling real-world studies, weight changed by the same amount with liraglutide and exenatide once weekly.

    Peptide
    Liraglutide
    Outcome
    No significant changePooled body weight change versus ExeOW
    Study

    n: not reported in source

    Comparator
    Exenatide once weekly
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pooling these data with those of observational studies available in the literature yielded superimposable effects between the two groups for the change in HbA1c and body weight, with a higher risk of discontinuation (mainly based on pharmacy refill rates) for ExeOW.
    1 context sentence
    Summary · context
    In this study, we retrospectively compared the effectiveness of exenatide once-weekly (ExeOW) versus liraglutide in non-insulin treated patients with type 2 diabetes followed under routine care.
  3. 03HumanSystematic reviewSafety outcome

    In a meta-analysis of observational studies, liraglutide had a lower risk of discontinuation than exenatide once weekly, mainly based on pharmacy refill rates.

    In plain wordsPooling real-world studies, fewer people stopped liraglutide than exenatide once weekly, mainly judged from pharmacy refills.

    Peptide
    Liraglutide
    Outcome
    DecreasePooled risk of discontinuation versus ExeOW
    Study

    n: not reported in source

    Comparator
    Exenatide once weekly
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pooling these data with those of observational studies available in the literature yielded superimposable effects between the two groups for the change in HbA1c and body weight, with a higher risk of discontinuation (mainly based on pharmacy refill rates) for ExeOW.
    1 context sentence
    Summary · context
    In this study, we retrospectively compared the effectiveness of exenatide once-weekly (ExeOW) versus liraglutide in non-insulin treated patients with type 2 diabetes followed under routine care.
  4. 04HumanObservational studyEfficacy outcome

    In non-insulin treated patients with type 2 diabetes under routine care, the change in HbA1c at 6 months was the same with liraglutide and exenatide once weekly.

    In plain wordsIn people with type 2 diabetes under routine care, HbA1c fell by the same amount with liraglutide and exenatide once weekly.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c change at 6 months versus ExeOW
    Study

    n = 614

    Comparator
    Exenatide once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −0.7%
    both groups

    Source sentences

    Summary
    Change in HbA1c at 6 months was superimposable in the two groups (-0.7% ± 1.0%)
    2 context sentences
    Summary · context
    In our multicentre retrospective study, patients initiating ExeOW (n = 204) or liraglutide (n = 410) had similar baseline clinical characteristics.
    Summary · context
    In this study, we retrospectively compared the effectiveness of exenatide once-weekly (ExeOW) versus liraglutide in non-insulin treated patients with type 2 diabetes followed under routine care.
  5. 05HumanObservational studyEfficacy outcome

    In non-insulin treated patients with type 2 diabetes under routine care, body weight changes were similar with liraglutide and exenatide once weekly.

    In plain wordsIn people with type 2 diabetes under routine care, weight changed by a similar amount with liraglutide and exenatide once weekly.

    Peptide
    Liraglutide
    Outcome
    No significant changeBody weight change at 6 months versus ExeOW
    Study

    n = 614

    Comparator
    Exenatide once weekly
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Body weight change
    −2.5 kg
    liraglutide
    Body weight change
    −2.2 kg
    exenatide once weekly

    Source sentences

    Summary
    changes in body weight were also similar (ExeOW -2.2 ± 3.7 kg; liraglutide -2.5 ± 4.3 kg; p = 0.457).
    2 context sentences
    Summary · context
    In our multicentre retrospective study, patients initiating ExeOW (n = 204) or liraglutide (n = 410) had similar baseline clinical characteristics.
    Summary · context
    In this study, we retrospectively compared the effectiveness of exenatide once-weekly (ExeOW) versus liraglutide in non-insulin treated patients with type 2 diabetes followed under routine care.
  6. 06HumanObservational studySafety outcome

    In non-insulin treated patients with type 2 diabetes under routine care, discontinuation rates were not significantly different between liraglutide and exenatide once weekly.

    In plain wordsIn people with type 2 diabetes under routine care, the number who stopped treatment was not significantly different between liraglutide and exenatide once weekly.

    Peptide
    Liraglutide
    Outcome
    No significant changeDiscontinuation rate versus ExeOW
    Study

    n = 614

    Comparator
    Exenatide once weekly
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Discontinuation rates were numerically but not significantly lower for ExeOW versus liraglutide.
    2 context sentences
    Summary · context
    In our multicentre retrospective study, patients initiating ExeOW (n = 204) or liraglutide (n = 410) had similar baseline clinical characteristics.
    Summary · context
    In this study, we retrospectively compared the effectiveness of exenatide once-weekly (ExeOW) versus liraglutide in non-insulin treated patients with type 2 diabetes followed under routine care.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    12 Oct 2026, 11:11 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.